Compare IDEXX Laboratories, Inc. (IDXX) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Rockwell Automation — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Rockwell Automation trades at $463.2 (market cap $51.04B). The key difference: IDEXX Laboratories, Inc. and Rockwell Automation are close in size by market cap, and Rockwell Automation pays a 1.2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | ROK | |
|---|---|---|
Market Cap | $44.48B | $51.04B |
Sector | Health | Industrials |
52-Week High | $766.68 | $495.08 |
52-Week Low | $520.87 | $328.67 |
Enterprise Value | $45.38B | $54.67B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Rockwell Automation (ROK) trades at $459.09, down 0.6% on the day, with a neutral technical signal despite bullish moving averages. The company maintains strong profitability with 48.9% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include partnerships in nuclear automation and recognition as a Global Lighthouse facility, positioning ROK for AI infrastructure growth.
ROK presents a mixed outlook with premium valuation metrics (P/E 48) offset by consistent earnings beats and AI-driven growth potential. Key risks include cyclical industrial exposure and competitive pressures, while analyst consensus at $471.71 suggests modest upside from current levels with 31% buy ratings indicating cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
